Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02791334
Recruitment Status : Recruiting
First Posted : June 6, 2016
Last Update Posted : April 22, 2020
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor Microsatellite Instability-High (MSI-H) Solid Tumors Cutaneous Melanoma Pancreatic Cancer Breast Cancer (HR+HER2-) Drug: LY3300054 Drug: Ramucirumab Drug: Abemaciclib Drug: Merestinib Drug: LY3321367 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 215 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Actual Study Start Date : June 29, 2016
Estimated Primary Completion Date : June 6, 2020
Estimated Study Completion Date : December 6, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LY3300054
LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
Drug: LY3300054
Administered IV

Experimental: LY3300054 + Ramucirumab
LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
Drug: LY3300054
Administered IV

Drug: Ramucirumab
Administered IV
Other Name: LY3009806

Experimental: Abemaciclib + LY3300054
LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
Drug: LY3300054
Administered IV

Drug: Abemaciclib
Administered orally
Other Name: LY2835219

Experimental: LY3300054 + Abemaciclib (Concurrent Dosing)
LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
Drug: LY3300054
Administered IV

Drug: Abemaciclib
Administered orally
Other Name: LY2835219

Experimental: LY3300054 + Abemaciclib
LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
Drug: LY3300054
Administered IV

Drug: Abemaciclib
Administered orally
Other Name: LY2835219

Experimental: LY3300054 + Merestinib
LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
Drug: LY3300054
Administered IV

Drug: Merestinib
Administered orally
Other Name: LY2801653

Experimental: LY3300054 Expansion (Metastatic Cutaneous Melanoma)
LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
Drug: LY3300054
Administered IV

Experimental: LY3300054 Expansion (MSI-H Solid Tumors)
LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
Drug: LY3300054
Administered IV

Experimental: : LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion
LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
Drug: LY3300054
Administered IV

Drug: Abemaciclib
Administered orally
Other Name: LY2835219

Experimental: LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)
LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
Drug: LY3300054
Administered IV

Drug: LY3321367
Administered IV

Experimental: LY3300054 + LY3321367 Expansion
LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
Drug: LY3300054
Administered IV

Drug: LY3321367
Administered IV

Experimental: LY3300054 + Merestinib (Pancreatic Cancer) Expansion
LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
Drug: LY3300054
Administered IV

Drug: Merestinib
Administered orally
Other Name: LY2801653




Primary Outcome Measures :
  1. Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs) [ Time Frame: Baseline through Cycle 1 (Approximately 28 Days) ]

Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3300054 [ Time Frame: Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) ]
  2. PK: Cmax of Ramucirumab [ Time Frame: Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) ]
  3. PK: Cmax of Abemaciclib [ Time Frame: Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) ]
  4. PK: Cmax of Merestinib [ Time Frame: Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) ]
  5. PK: Cmax of LY3321367 [ Time Frame: Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) ]
  6. Objective Response Rate (ORR): Proportion of Participants With a Complete Response (CR) or Partial Response (PR) [ Time Frame: Baseline to Measured Progressive Disease (Approximately 6 Months ) ]
  7. Progression Free Survival (PFS) [ Time Frame: Baseline to Measured Progressive Disease or Death (Approximately 12 Months) ]
  8. Duration of Response (DoR) [ Time Frame: Date of CR or PR to Date of Measured Progressive Disease or Death Due to Any Cause (Approximately 12 Months) ]
  9. Time to Response (TTR) [ Time Frame: Baseline to Date of CR or PR (Approximately 6 Months) ]
  10. Disease Control Rate (DCR): Proportion of Participants who Exhibit Stable Disease (SD), CR or PR [ Time Frame: Baseline to Measured Progressive Disease (Approximately 6 Months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic or cytologic confirmation of advanced solid tumor.
  • For LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin.
  • For LY3300054 + abemaciclib in HR+, HER- breast cancer:

    • Express at least 1 of the hormone receptors [HR; estrogen receptor (ER) or progesterone receptor (PR)] by immunohistochemistry (IHC) to fulfill the requirement for HR+ disease on the primary tumor or metastatic lesion of the breast cancer. ER and PR assays are considered positive if there is at least 1% positive tumor nuclei in their sample as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) or local guidelines.
    • To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization (ISH) as defined in the relevant ASCO/CAP or local guidelines.
    • Most recent HR and HER2 receptor testing should be used to determine eligibility.
    • Have previously received prior treatment with at least 1 but no more than 3 chemotherapy regimens in the metastatic setting.
    • Have AST, ALT, GGT, and AP that are ≤2.5x upper limit of normal (ULN) and normal bilirubin (total and direct) regardless of liver involvement.
  • For LY3300054 + merestinib in pancreatic cancer:

    • Histologically or cytological confirmed diagnosis of metastatic or locally advanced, unresectable pancreatic adenocarcinoma (excluding other pancreatic malignancies for example, acinar cell carcinomas, adenosquamous carcinomas, and neuroendocrine islet cell neoplasms).
    • Have had disease progression, be refractory or intolerant to no more than 2 prior systemic regimens.
  • For LY3300054 + LY3321367 in PD-1/PD-L1-naive, MSI-H/MMR-deficient advanced solid tumors:

    • Have histologically or cytologically confirmed diagnosis of advanced solid tumor AND shown to be MSI-H or MMR-deficient.
  • For LY3300054 + LY3321367 in PD-1/PD-L1- resistant/refractory, MSI-H/MMR-deficient advanced solid tumors:

    • Have histologically or cytologically confirmed diagnosis of advanced solid tumor AND shown to be MSI-H or MMR-deficient.
    • Prior exposure to PD-1/PD-L1 agent regardless of response.
  • For Phase 1b LY3300054 monotherapy or combination therapy, no prior treatment with a PD-1 or PD-L1 agent is allowed.

    • Exception: the LY3321367 combination in participants with PD-1/PD-L1- resistant/refractory, MSI-H, where prior exposure to PD-1/PD-L1 agent required.
  • For Phase 1a LY3300054 monotherapy or combination therapy, previous immunotherapy is acceptable if the following criteria are met:

    • Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
    • Must have completely recovered or recovered to baseline prior to screening from any prior adverse events (AEs) occurring while receiving prior immunotherapy.
    • Must not have experienced a Grade ≥3 immune-related AE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy.
    • Must not have required the use of additional immunosuppressive agents other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of >10 milligrams prednisone or equivalent per day.
  • Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Have adequate organ function.
  • Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
  • Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator.
  • Have submitted a tumor tissue sample, as follows:

    • For participants entering the Phase 1a dose escalation: have submitted, if available, the most recent archival tumor tissue sample.
    • For those participating ONLY in Phase 1b expansions: Have submitted tumor tissue sample from a newly obtained core or excisional biopsy for a tumor lesion (preferred) or a recent biopsy taken with 3 months prior to study enrollment and following the participants most recent prior systemic treatment and be willing to undergo a biopsy procedure during the study treatment period for collection of additional tumor tissue sample.

Exclusion Criteria:

  • Have a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids.
  • Have a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection or chronic diarrhea.
  • Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis.
  • Have an active infection requiring systemic therapy.
  • Have moderate or severe cardiovascular disease.
  • Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment.
  • Have received a live vaccine within 30 days before the first dose of study treatment.
  • Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02791334


Contacts
Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Locations
Layout table for location information
United States, Tennessee
Sarah Cannon Research Institute SCRI Recruiting
Nashville, Tennessee, United States, 37203
Contact    615-329-7274      
Principal Investigator: SMO Sarah Cannon Research Inst.         
Tennessee Oncology PLLC Recruiting
Nashville, Tennessee, United States, 37203
Contact    6153297274      
Principal Investigator: Johanna Chock Bendell         
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Timothy Yap         
The START Center for Cancer Care Recruiting
San Antonio, Texas, United States, 78229
Contact    210-593-5270      
Principal Investigator: Amita Patnaik         
Belgium
Cliniques Universitaires Saint-Luc Recruiting
Brussels, Belgium, 1200
Contact    327645106      
Principal Investigator: Jean-Pascal Machiels         
Universitair Ziekenhuis Antwerpen Recruiting
Edegem, Belgium, 2650
Contact    3238213954      
Principal Investigator: Marc Peeters         
Canada, Ontario
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5TY 2M9
Contact    4169464501      
Principal Investigator: Neesha Dhani         
France
Institut Bergonie Recruiting
Bordeaux, France, 33076
Contact    33556333253      
Principal Investigator: Antoine Italiano         
Gustave Roussy Recruiting
Villejuif Cedex, France, 94805
Contact    33142114385      
Principal Investigator: Antoine Hollebecque         
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 03080
Contact    82220722390      
Principal Investigator: Sae Won Han         
Severance Hospital Yonsei University Health System Recruiting
Seoul, Korea, Republic of, 03722
Contact    82222288132      
Principal Investigator: Hyun Cheol Chung         
Spain
Fundacion Jimenez Diaz Recruiting
Madrid, Spain, 28040
Contact    34915504800      
Principal Investigator: Victor Moreno         
Hospital Madrid Norte Sanchinarro Recruiting
Madrid, Spain, 28050
Contact    34917567825      
Principal Investigator: Maria Jose Miguel Luken         
Taiwan
National Cheng Kung University Hospital Recruiting
Tainan, Taiwan, 70403
Contact    88662353535      
Principal Investigator: Wu-Chou Su         
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 10048
Contact    +886223123456 ext. 67680      
Principal Investigator: Chia-Chi Lin         
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Additional Information:
Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT02791334    
Other Study ID Numbers: 16088
I8J-MC-JYCA ( Other Identifier: Eli Lilly and Company )
2016-000440-33 ( EudraCT Number )
First Posted: June 6, 2016    Key Record Dates
Last Update Posted: April 22, 2020
Last Verified: April 1, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eli Lilly and Company:
PDL1
PD-L1
Additional relevant MeSH terms:
Layout table for MeSH terms
Microsatellite Instability
Neoplasms
Genomic Instability
Pathologic Processes
Ramucirumab
Antineoplastic Agents